Postoperative enrollment
PD, SD, breast cancer
METASTASIS, LYMPH NODE METASTASES, BREAST CANCER, DISEASE, PRIMARY TUMOR
Patients with a clinical response to LET including complete response (CR), partial response (PR), or stable disease (SD), and who completed breast cancer surgical treatment, with lymph node-negative or -positive disease (1–3 nodes) were enrolled. If the primary tumor did not show progressive disease (PD), patients with 1–3 lymph node metastases were included in the randomized cohort without judging them as PD, assuming that they had metastasis from the beginning. Patients with HER2+ in a surgical specimen were excluded.